BMRN vs. LLY
Compare and contrast key facts about BioMarin Pharmaceutical Inc. (BMRN) and Eli Lilly and Company (LLY).
Performance
BMRN vs. LLY - Performance Comparison
Loading graphics...
BMRN vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BMRN BioMarin Pharmaceutical Inc. | -4.95% | -9.58% | -31.83% | -6.83% | 17.14% | 0.75% | 3.71% | -0.70% | -4.51% | 7.64% |
LLY Eli Lilly and Company | -14.27% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Fundamentals
BMRN:
$11.15B
LLY:
$825.96B
BMRN:
$1.79
LLY:
$22.96
BMRN:
31.63
LLY:
40.06
BMRN:
1.89
LLY:
0.81
BMRN:
3.43
LLY:
12.68
BMRN:
1.83
LLY:
31.13
BMRN:
$3.22B
LLY:
$65.18B
BMRN:
$2.48B
LLY:
$54.62B
BMRN:
$613.03M
LLY:
$27.94B
Returns By Period
In the year-to-date period, BMRN achieves a -4.95% return, which is significantly higher than LLY's -14.27% return. Over the past 10 years, BMRN has underperformed LLY with an annualized return of -3.97%, while LLY has yielded a comparatively higher 30.92% annualized return.
BMRN
- 1D
- 3.10%
- 1M
- -8.49%
- YTD
- -4.95%
- 6M
- 4.30%
- 1Y
- -20.09%
- 3Y*
- -16.56%
- 5Y*
- -6.21%
- 10Y*
- -3.97%
LLY
- 1D
- 3.74%
- 1M
- -12.57%
- YTD
- -14.27%
- 6M
- 20.93%
- 1Y
- 12.19%
- 3Y*
- 39.90%
- 5Y*
- 39.16%
- 10Y*
- 30.92%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BMRN vs. LLY — Risk / Return Rank
BMRN
LLY
BMRN vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BMRN | LLY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.57 | 0.29 | -0.85 |
Sortino ratioReturn per unit of downside risk | -0.70 | 0.69 | -1.39 |
Omega ratioGain probability vs. loss probability | 0.92 | 1.10 | -0.18 |
Calmar ratioReturn relative to maximum drawdown | -0.77 | 0.42 | -1.19 |
Martin ratioReturn relative to average drawdown | -1.07 | 1.02 | -2.09 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BMRN | LLY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.57 | 0.29 | -0.85 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.19 | 1.23 | -1.42 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.11 | 1.04 | -1.15 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.11 | 0.56 | -0.45 |
Correlation
The correlation between BMRN and LLY is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
BMRN vs. LLY - Dividend Comparison
BMRN has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMRN BioMarin Pharmaceutical Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.68% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Drawdowns
BMRN vs. LLY - Drawdown Comparison
The maximum BMRN drawdown since its inception was -90.58%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for BMRN and LLY.
Loading graphics...
Drawdown Indicators
| BMRN | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.58% | -68.24% | -22.34% |
Max Drawdown (1Y)Largest decline over 1 year | -24.68% | -30.26% | +5.58% |
Max Drawdown (5Y)Largest decline over 5 years | -56.12% | -34.48% | -21.64% |
Max Drawdown (10Y)Largest decline over 10 years | -60.73% | -34.48% | -26.25% |
Current DrawdownCurrent decline from peak | -62.12% | -17.00% | -45.12% |
Average DrawdownAverage peak-to-trough decline | -45.39% | -19.25% | -26.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.57% | 12.39% | +7.18% |
Volatility
BMRN vs. LLY - Volatility Comparison
The current volatility for BioMarin Pharmaceutical Inc. (BMRN) is 8.06%, while Eli Lilly and Company (LLY) has a volatility of 9.04%. This indicates that BMRN experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BMRN | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.06% | 9.04% | -0.98% |
Volatility (6M)Calculated over the trailing 6-month period | 25.04% | 26.21% | -1.17% |
Volatility (1Y)Calculated over the trailing 1-year period | 35.67% | 42.44% | -6.77% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.21% | 32.14% | +0.07% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 35.65% | 29.80% | +5.85% |
Financials
BMRN vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between BioMarin Pharmaceutical Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMRN vs. LLY - Profitability Comparison
BMRN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, BioMarin Pharmaceutical Inc. reported a gross profit of 579.47M and revenue of 874.57M. Therefore, the gross margin over that period was 66.3%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.
BMRN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, BioMarin Pharmaceutical Inc. reported an operating income of 79.39M and revenue of 874.57M, resulting in an operating margin of 9.1%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.
BMRN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, BioMarin Pharmaceutical Inc. reported a net income of -46.57M and revenue of 874.57M, resulting in a net margin of -5.3%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.